IP Library › Granted Patent US 11,590,219
Granted Patent B2
US 11,590,219 · App. 16/966,387 · Granted Feb 28, 2023

Compositions and methods for promoting immune responses to human immunodeficiency virus

Inventors: Rama Rao Amara (Decatur, GA); Andrew Jones (Atlanta, GA); Raghavan Varadarajan (Bengaluru, IN)
Assignee: Emory University
A61K39/21C07K14/162C12N7/00A61K2039/53C12N2710/24143C12N2740/16034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,219
App. No.
16/966,387
Granted
Feb 28, 2023
Kind
B2
Abstract

This disclosure relates to methods of promoting immune responses against HIV and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for HIV comprising administering to the subject a priming composition followed by a boosting composition. In certain embodiments, the priming composition comprises a recombinant virus such as recombinant MVA that encodes an Env protein of HIV or segment thereof. In certain embodiments, the boosting composition comprises a trimeric cyclically permuted gp120 chimeric protein reported herein or DNA encoding the same.

Claims (57)

1. A method of vaccinating comprising:

i) administering to a subject a nucleic acid and/or recombinant virus that encodes an HIV Env protein or segment thereof under conditions such that virus-like particles with surface gp120 proteins are formed in the subject;

ii) administering to the subject an effective amount of a chimeric protein comprising an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, and;

wherein administering is to the buccal cavity propelled through the skin or soft tissue lining of the mouth with pressure.

2. The method of claim 1 , wherein administering to the subject an effective amount of the chimeric protein is more than one week after administering to a subject a nucleic acid or recombinant virus that encodes HIV Env protein or segment thereof.

3. A composition comprising a chimeric protein comprising an amino acid sequence

(SEQ ID NO: 2)

EEDPCACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVVASSEG

TMMRGELKNCSFNMTTELRDKKQKVYSLFYRLDVVQINENQGNRSNNS

NKEYRLINCNTSAITQACPKVSFEPIPIHYCAPAGFAILKCKDKKFNG

TGPCPSVSTVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSENITNNAKN

ILVQFNTPVQINCTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHCN

VSKATWNETLGKVVKQLRKHFGNNTIIRFANSSGGDLEVTTHSFNCGG

EFFYCNTSGLFNSTWISNTSVQGSNSTGSNDSITLPCRIKQIINMAAA

WQRIGQAMYAPPIQGVIRCVSNITGLILTRDGGSTNSTTETFRPGGGD

MRDNWRSELYKYKVVKIEPLGVAPTRAKRRVVGREKRGSAGSAGSSRS

AGSAGSAGSEIHLENVTEEFNMWKNNMVEQMFITDIISLWDQSLKPCV

KLTPLCVTLQCTNVTNNITDDAAA.

4. A composition comprising a chimeric protein comprising an amino acid sequence

(SEQ ID NO: 3)

EEDPCACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVVASSVN

VTNGEEIKNCSFNATTEIRDKKQKVYALFYRLDIVPLEEERKGNSSKY

RLINCNTSAITQACPKVTFDPIPIHYCAPAGYAILKCNNKTFNGTGPC

NNVSTVQCTHGIKPVVSTQLLLNGSLAEGEIIIRSENLTNNVKTIIVH

LNESVEIVCTRPNNNTRKSIRIGPGQTFYATGDIIGNIRQAYCNIKKD

DWIRTLQRVGKKLAEHFPRRIINFTSPAGGDLEITTHSFNCRGEFFYC

NTSSLFNSTYNPNDTNSNSSSSNSSLDITIPCRIKQIINMWQEVGRAM

YAPPIEGNITCKSNITGLLLVRDGGVESNETEIFRPGGGDMRNNWRSE

LYKYKVVEIKPLGIAPTAAKRRVVEREKRGSAGSAGSSRSAGSAGSAG 

SEMVLENVTENFNMWKNDMVEQMHEDVISLWDQSLKPCVKLTPLCVTL

ECRQVNTTNATSAAA.

5. A composition comprising a chimeric protein comprising an amino acid sequence

(SEQ ID NO: 4)

EEDPCACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVVASSVN

VTNGEVMKNCSFNATTELKDKKHKVHALFYKLDVVPLNGNSSSSGEYR

LINCNTSAITQACPKVSFDPIPLHYCAPAGFAILKCNNKTFNGTGPCR

NVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNAKTIIVHL

NESVNINCTRPNNNTRKSIRIGPGQTFYATGDIIGNIRQAHCNINESK

WNNTLQKVGEELAKHFPSKTIKFEPSSGGDLEITTHSFNCRGEFFYCN

TSDLFNGTYRNGTYNHTGRSSNGTITLQCKIKQIINMWQEVGRAIYAP

PIEGEITCNSNITGLLLLRDGGQSNETNDTETFRPGGGDMRDNWRSEL

YKYKVVEIKPLGVAPTEAKRRVVEREKRGSAGSAGSSRSAGSAGSAGS

EMVLANVTENFNMWKNDMVEQMHEDIISLWDESLKPCVKLTPLCVTLN

CTNVKGNESDTAAA.

6. A composition comprising a chimeric protein comprising an amino acid sequence

(SEQ ID NO: 5)

EEDPCACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVVASSVN

VTNGEEIKNCSFNTTTEIRDKKQKEYALFYRLDIVPLNEERKGNSSEY

RLINCNTSTITQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPC

NNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNAKTIIVH

LNESVEINCTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHCNISES

KWNKTLQRVSKKLKEHFPNKTIKFAPSSGGDLEITTHSFNCRGEFFYC

NTSKLFNSTYNNNTSNSTITLPCRIKQIINMWQEVGRAMYAPPIAGNI

TCKSNITGLLLTRDGGNNNNTTETFRPGGGDMRDNWRSELYKYKVVEI

KPLGIAPTKAKRRVVEREKRGSAGSAGSSRSAGSAGSAGSEMVLENVT

ENFNMWKNDMVDQMHEDTTSLWDQSLKPCVKLTPLCVTLNCTNVNVTN

ATSAAA.

Continuity (2)
Provisional Application 62623986 · Jan 30, 2018
Related Publication 20200368348A1 · Nov 26, 2020
Cited By (1)
US 12,194,088